Author’s note: I'm very grateful to President and CEO Allen Baharaff, Dr. Liat Hayardeny and management for the call interview.
Investment Thesis
Galmed (GLMD) is a small market cap ($177M) Israeli clinical stage biopharma focused on the clinical development of its lead investigative drug candidate, Aramchol (arachidyl amido cholanoic acid). Aramchol belongs to the Fatty Acid Bile Acid Conjugate (FABAC) family and is being clinically assessed in NASH, a progressive chronic fibrotic liver disease with high unmet needs and no FDA-approved therapeutic options. Galmed’s scientific forte is the clinical development “of innovative†proprietary